SCHEMBL2729193

SCHEMBL2729193

NC(=O)c1ccc(Cl)nc1Nc1ccc2[nH]ncc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 5/20 0.59
▸ MKNK1 Q9BUB5 2/20 0.51
▸ NPC1 O15118 2/20 0.50
▸ JAK2 O60674 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ JAK3 P52333 1/20 0.50
▸ IRAK4 Q9NWZ3 1/20 0.50
▸ JAK1 P23458 1/20 0.50
▸ ROCK2 O75116 4/20 0.49
▸ ROCK1 Q13464 4/20 0.49
▸ PRKD3 O94806 1/20 0.49
▸ MAP4K4 O95819 1/20 0.49
▸ RPS6KB1 P23443 1/20 0.49
▸ CLK2 P49760 1/20 0.49
▸ DYRK1A Q13627 1/20 0.49
▸ PRKG1 Q13976 1/20 0.49
▸ PRKD2 Q9BZL6 1/20 0.49
▸ CLK4 Q9HAZ1 1/20 0.49
▸ SGK2 Q9HBY8 1/20 0.49
▸ STK17A Q9UEE5 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14955969 0.82 MKNK1 (0.53) SYKMKNK1NPC1JAK2RAB9A
SCHEMBL5856980 0.79 ROCK2 (0.55) SYKNPC1JAK2RAB9AJAK3
SCHEMBL5413116 0.78 JAK3 (0.62) SYKNPC1JAK2RAB9AJAK3
SCHEMBL6771473 0.77 SYK (0.66) SYKMKNK1JAK3IRAK4ROCK2
SCHEMBL10241915 0.77 SYK (0.73) SYKJAK3IRAK4PRKD3MAP4K4
SCHEMBL10242654 0.77 SYK (0.73) SYKJAK3IRAK4PRKD3MAP4K4
SCHEMBL4560491 0.76 SYK (0.59) SYKNPC1RAB9AJAK3PRKD3
SCHEMBL6789738 0.76 HSF1 (0.72) MKNK1ROCK2ROCK1PRKD3MAP4K4
SCHEMBL10250612 0.76 SYK (0.56) SYKMKNK1JAK2JAK3IRAK4
SCHEMBL13624988 0.76 SYK (0.69) SYKJAK3IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9902688-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2018-02-27 — — US disclosed
EP-3176154-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2017-06-07 — — EP disclosed
US-20160318852-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS ALEXION PHARMACEUTICALS, INC. 2016-11-03 — — US disclosed
US-9359375-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-20150038492-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-02-05 — — US disclosed
US-8846928-B2 Benzamides and nicotinamides as Syk modulators PORTOLA PHARMACEUTICALS, INC. (US) 2014-09-30 — — US disclosed
EP-2635556-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 — — EP disclosed
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-07 — — US disclosed
WO-2012061418-A2 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142671-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK SYK 1/4885MKNK1 1762/4885NPC1 2028/4885
US-20160318852-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK SYK 1/4885MKNK1 1762/4885NPC1 2028/4885
US-20150038492-A1 BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS SYK, BTK, NADK SYK 1/4885MKNK1 1762/4885NPC1 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback